Quest Diagnostics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.54B | $9.25B | $9.89B | $10.79B | $9.44B | $7.72B | $7.53B |
| Diagnostic Information Services | — | $9.08B | $8.79B | $9.42B | $10.25B | $8.95B | $7.33B | $7.17B |
| Diagnostic Solutions | — | $466.0M | $457.0M | $467.0M | $542.0M | $488.0M | $391.0M | $360.0M |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B |
| Gross Profit | $3.67B | $2.91B | $3.05B | $3.44B | $4.21B | $3.63B | $2.69B | $2.61B |
| Gross Margin | 33.2% | 30.5% | 33.0% | 34.7% | 39.0% | 38.5% | 34.8% | 34.6% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B |
| Operating Margin | 14.1% | 14.1% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% |
| Interest Expense | — | — | $163.0M | $148.0M | $152.0M | $166.0M | $180.0M | $169.0M |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926.0M |
| Income Tax Expense | $314.0M | $273.0M | $248.0M | $264.0M | $597.0M | $460.0M | $247.0M | $182.0M |
| Net Income | $992.0M | $871.0M | $854.0M | $946.0M | $2.00B | $1.43B | $858.0M | $736.0M |
| Net Margin | 9.0% | 9.1% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 |
| Shares Outstanding (Basic) | 111.0M | 111.0M | 112.0M | 116.0M | 125.0M | 134.0M | 134.0M | 136.0M |
| Shares Outstanding (Diluted) | 113.0M | 113.0M | 113.0M | 118.0M | 128.0M | 136.0M | 136.0M | 139.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |